MolPort-000-883-877

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

45 Suppliers, 24 USDMF, 11 CEP/COS, 9 EU WC, 3 KDMF, 9 NDC API, 22 Listed Suppliers

DEVELOPMENTS

59 Drug(s) in Development

59 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

5 Suppliers

5 Suppliers

DOSSIERs // Finished Dosage Forms

100 Dossiers, 40 FDA Orange Book, 15 Europe, 7 Canada, 4 Australia, 20 South Africa, 14 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 100MG;25MG, TABLET;ORAL - 200MG;50MG, TABLET;ORAL - 100MG

RELATED EXCIPIENT COMPANIES

Suppliers, 17 BASF, 15 Seppic, 14 Kerry, 13 Gangwal Chemicals, 12 Corel Pharma Chem, 8 Nanjing Well Pharmaceutical, 7 Actylis, 6 Lonza Capsugel, 6 Ideal Cures Pvt Ltd, 4 Gangwal Healthcare, 4 ACG Worldwide, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 4 Microlex e.U, 4 Boai NKY Pharmaceuticals Ltd, 3 Rochem International Inc, 3 Roquette, 3 Kima Chemical, 2 The Dow Chemical Company, 2 Jai Radhe Sales, 2 Bioplus Life Sciences, 2 Pharmatrans-Sanaq, 2 Qualicaps, 2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 2 DKSH, 2 Nanjing Bold Chemical, 2 Alcedo Pharmachem, 2 Sigachi Industries, 2 Ulanqab Kema New Material, 1 Aeon Procare, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Prachin Chemical, 1 NEWEDGE Overseas, 1 Pharm-RX Chemical, 1 Clariant, 1 Chynops Pharma, 1 PMC Isochem, 1 Finar, 1 Zhejiang Huakang Pharmaceutical, 1 Minakem, 1 Huzhou Sunflower Pharmaceutical Co. Ltd, 1 SPI Pharma, 1 Seqens

EXCIPIENTS BY APPLICATIONS

49 Coating Systems & Additives, 33 Solubilizers, 26 Fillers, Diluents & Binders, 25 Controlled & Modified Release, 20 Parenteral, 20 Film Formers & Plasticizers, 15 Topical, 13 Direct Compression, 12 Emulsifying Agents, 12 Lubricants & Glidants, 12 Taste Masking, 11 Granulation, 10 API Stability Enhancers, 9 Thickeners and Stabilizers, 9 Empty Capsules, 8 Disintegrants & Superdisintegrants, 6 Surfactant & Foaming Agents, 4 Co-Processed Excipients, 4 Vegetarian Capsules, 3 Rheology Modifiers, 3 Chewable & Orodispersible Aids, 2 Coloring Agents

GLOBAL SALES INFORMATION

15 US Medicaid Prescriptions, 12 Finished Drug Prices

MARKET PLACE

24 APIs, 9 DOSSIERS // FDF

PATENTS

31 US Patents, 16 Health Canada Patents

ANALYTICAL SOLUTION(s)

2 BioAnalytical Methods, 2 EDQM Standards, 2 USP Standards, 3 Other Ref. Standards

DIGITAL CONTENT

4 Data Compilation & Company Tracker #PharmaFlow, 152 News, 1 Monthly Stock Recap #PipelineProspector

Information, Expiry & Status of Health Canada Patents covering MolPort-000-883-877.

MolPort-000-883-877

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

45 Suppliers

24 USDMF

11 CEP/COS

9 EU WC

3 KDMF

9 NDC API

22 Listed Suppliers

DEVELOPMENTS

59 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

FDF Imports

INTERMEDIATES

5 Suppliers

DOSSIERs // Finished Dosage Forms

100 Dossiers

40 FDA Orange Book

15 Europe

7 Canada

4 Australia

20 South Africa

14 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - 12.5MG;75MG;50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 100MG;25MG

TABLET;ORAL - 200MG;50MG

TABLET;ORAL - 100MG

RELATED EXCIPIENT COMPANIES

Suppliers

17 BASF

15 Seppic

14 Kerry

13 Gangwal Chemicals

12 Corel Pharma Chem

8 Nanjing Well Pharmaceutical

7 Actylis

6 Lonza Capsugel

6 Ideal Cures Pvt Ltd

4 Gangwal Healthcare

4 ACG Worldwide

4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

4 Microlex e.U

4 Boai NKY Pharmaceuticals Ltd

3 Rochem International Inc

3 Roquette

3 Kima Chemical

2 The Dow Chemical Company

2 Jai Radhe Sales

2 Bioplus Life Sciences

2 Pharmatrans-Sanaq

2 Qualicaps

2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

2 DKSH

2 Nanjing Bold Chemical

2 Alcedo Pharmachem

2 Sigachi Industries

2 Ulanqab Kema New Material

1 Aeon Procare

1 Qianhao Chemical (Hebei) Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Prachin Chemical

1 NEWEDGE Overseas

1 Pharm-RX Chemical

1 Clariant

1 Chynops Pharma

1 PMC Isochem

1 Finar

1 Zhejiang Huakang Pharmaceutical

1 Minakem

1 Huzhou Sunflower Pharmaceutical Co. Ltd

TABLET;ORAL - 12.5MG;75MG;50MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - EQ 200MG BASE;8.33MG;50MG;33.33MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

CAPSULE;ORAL - 100MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons